by Rod Raynovich | Dec 2, 2010 | BIOgraph
Contrarian Call -Look at the Drug Stocks The healthcare sector has lagged the market in 2010 down about 1.34% compared to the S&P up about 9%. The large cap drug sector has done worse down 4.3%. Investors are drawn to more dynamic growth sectors in 2010: energy,...
by Rod Raynovich | Dec 1, 2010 | 2024-25 Life Science Portfolios, BIOgraph
SeraCare Reports 40% Increase in Net Income Over Prior Year SeraCare (SRLS) executed six consecutive quarters of successful growth with revenue growth of 13% to $50.4 M for the fiscal year ending SEP 30, compared to revenues of $44.4M year in 2009. Net Income was...
by Rod Raynovich | Nov 30, 2010 | BIOgraph
Restructuring Play in Diagnostics at a VC Valuation Vermilion(VRML) technology utilizes a panel of biomarkers integrated with multivariate analysis software to develop disease specific assays. The R&D effort leverages collaborations with institutions such as...
by Rod Raynovich | Nov 30, 2010 | 2024-25 Life Science Portfolios, BIOgraph
Gen-Probe (GPRO,$51.60) announced yesterday that it submitted a Premarket Approval Application(PMA) the the FDA for its APTIMA HPV (human papillomavirus ) assay , a molecular diagnostic test that detects high-risk HPV infections that are associated with cervical...
by Rod Raynovich | Nov 29, 2010 | BIOgraph, Reading List
“A Deadly Misdiagnosis” by Michael Specter An interesting article in the November 15 New Yorker on the Tuberculosis epidemic in India stresses the need for more accurate diagnostic tests and how the Cepheid TB assay can save lives. The author reports on...
by Rod Raynovich | Nov 26, 2010 | BIOgraph
Here are some relevant news in areas that we previously covered: Biomarkers Genzyme (GENZ) licensed a lung cancer test under development to Roche and can target a patient’s response to their Tarceva cancer drug. The goal is a test for epidermal growth- factor...
by Rod Raynovich | Nov 22, 2010 | 2024-25 Life Science Portfolios, BIOgraph
Regeneron(REGN $28) stock soared today on two parallel Phase 3 studies with patients who had neovascular age related macular degeneration(wet AMD), the VEGF Trap Eye drug successfully met the endpoint compared to the current standard of care, ranibizumab dosed every...
by Rod Raynovich | Nov 18, 2010 | 2024-25 Life Science Portfolios, BIOgraph
Exelixis (EXEL) stock was up over 30% today to $6.14 on positive data from two experimental cancer drugs for prostate and ovarian cancer. The XL 184 drug showed promising results with castration-resistant prostate cancer (CRPC) achieving either partial or complete...
by Rod Raynovich | Nov 17, 2010 | 2024-25 Life Science Portfolios, BIOgraph
Microfluidics reported revenues of $4.1M for Q3 2010 ended Sep 30 a decrease of 9% or $500k compared to the same period of 2009. Excluding revenues of $1.3M attributed to machine production of the 2009 H1N1 Flu pandemic, revenues grew 29%.Unit sales increased to 144...
by Rod Raynovich | Nov 8, 2010 | 2024-25 Life Science Portfolios, BIOgraph
Immucor (BLUD) stock was up 5.7% to $18.91 on news that the DOJ closed its anti-trust investigation. The stock hit a low in early October when it slashed guidance due to lower utility of blood transfusion services.The Company is a leader in automated blood...
